1. |
Redman MW, Allegra CJ. The master protocol concept. Semin Oncol, 2015, 42(5): 724-730.
|
2. |
Tang R, Shen J, Yuan Y. ComPAS: a Bayesian drug combination platform trial design with adaptive shrinkage. Stat Med, 2019, 38(7): 1120-1134.
|
3. |
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med, 2017, 377(1): 62-70.
|
4. |
Meyer EL, Mesenbrink P, Dunger-Baldauf C, et al. The evolution of master protocol clinical trial designs: a systematic literature review. Clin Ther, 2020, 42(7): 1330-1360.
|
5. |
U. S. Food and Drug Administration. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics. Available at: https://www.fda.gov/media/120721/download.
|
6. |
Hirakawa A, Asano J, Sato H, et al. Master protocol trials in oncology: review and new trial designs. Contemp Clin Trials Commun, 2018, 12: 1-8.
|
7. |
Ledford H. 'Master protocol' aims to revamp cancer trials. Nature, 2013, 498(7453): 146-147.
|
8. |
胡嘉元, 张晓雨, 赵晨, 等. 母方案设计用于冠心病中医药防治方案循证优化的思路和实施方法. 中国循证医学杂志, 2019, 19(1): 102-106.
|
9. |
Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study. Rationale and design. Ann Am Thorac Soc, 2020, 17(7): 879-891.
|
10. |
U. S. Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics. Available at: https://www.fda.gov/media/78495/download.
|
11. |
于亚南, 杜培艳, 刘骏, 等. 精准医学创新性临床试验设计. 中国新药杂志, 2020, 29(23): 2712-2717.
|
12. |
Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov, 2019, 18(10): 797-807.
|
13. |
RECOVERY Central Coordinating Office. RECOVERY protocol V13.0. Available at: https://www.recoverytrial.net/files/recovery-protocol-v13-0-2021-01-26.pdf.
|
14. |
衡明莉, 王北琪, 王骏. 对美国FDA适应性设计指导原则的介绍. 中国临床药理学杂志, 2019, 35(12): 1316-1320.
|
15. |
Cerqueira FP, Jesus AMC, Cotrim MD. Adaptive design: a review of the technical, statistical, and regulatory aspects of implementation in a clinical trial. Ther Innov Regul Sci, 2020, 54(1): 246-258.
|
16. |
Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics, 1995, 51(4): 1315-1324.
|
17. |
Asendorf T, Henderson R, Schmidli H, et al. Sample size re-estimation for clinical trials with longitudinal negative binomial counts including time trends. Stat Med, 2019, 38(9): 1503-1528.
|
18. |
Denne JS. Sample size recalculation using conditional power. Stat Med, 2001, 20(17-18): 2645-2660.
|
19. |
Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials, 2019, 20(1): 572.
|
20. |
Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther, 2009, 86(1): 97-100.
|
21. |
Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA, 2015, 313(16): 1619-1620.
|
22. |
Herbst RS, Gandara DR, Hirsch FR, et al. Lung master protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res, 2015, 21(7): 1514-1524.
|
23. |
Steuer CE, Papadimitrakopoulou V, Herbst RS, et al. Innovative clinical trials: the LUNG-MAP Study. Clin Pharmacol Ther, 2015, 97(5): 488-491.
|
24. |
Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA, 2020, 324(13): 1317-1329.
|
25. |
RECOVERY Central Coordinating Office. RECOVERY protocol V1.0. Available at: https://www.recoverytrial.net/files/protocol-archive/recovery-protocol-v1-0-2020-03-18-final.pdf.
|